Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330

Published: 11/01/2019
Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330
Source: WWW.PRNEWSWIRE.COM

UPPSALA, Sweden, Jan. 11, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that ...

Read more
Related news
Comment
FACEBOOK